New York J 2064: Memorializing Governor Kathy Hochul to proclaim April 17-23, 2022, as Volunteer Week in the State of New York

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
J02064 Summary:

BILL NOJ02064 

&nbsp

SAME ASNo Same As

&nbsp

SPONSORPERSAUD

&nbsp

COSPNSR

&nbsp

MLTSPNSR

&nbsp

&nbsp

Go to top J02064 Actions:

BILL NOJ02064 

&nbsp

05/06/2026REFERRED TO FINANCE

05/12/2026REPORTED TO CALENDAR FOR CONSIDERATION

05/12/2026ADOPTED

Go to topJ02064 Committee&nbspVotes:

Go to topJ02064 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topJ02064 Text:

Senate Resolution No. 2064

BY: Senator PERSAUD

 MEMORIALIZING Governor Kathy Hochul to proclaim
 September 2026, as Blood Cancer Awareness Month in
 the State of New York

 WHEREAS, It is the custom of this Legislative Body to recognize
official months that are set aside to increase awareness of serious
illnesses that affect the lives of citizens of New York State; and

 WHEREAS, Attendant to such concern, and in full accord with its
long-standing traditions, it is the sense of this Legislative Body to
memorialize Governor Kathy Hochul to proclaim September 2026, as Blood
Cancer Awareness Month in the State of New York, in conjunction with the
observance of National Blood Cancer Awareness Month; and

 WHEREAS, During September, National Blood Cancer Awareness Month
sheds light on the cancers that affect the blood and lymphatic systems;
and

 WHEREAS, This vital observance focuses its attention on all blood
cancers-including, but not limited to, leukemia (including chronic
lymphocytic leukemia (CLL)), lymphoma, Waldenstrom macroglobulinemia,
multiple myeloma, myelodysplastic syndromes, and other related
hematologic malignancies-by raising awareness, the goal is to inform the
public about the causes of blood cancers, how to identify symptoms,
available treatments, and progress made through research;

 WHEREAS, CLL, the most common adult leukemia, is a chronic and often
incurable disease requiring ongoing management, with patients facing
unique challenges including active surveillance, risk of infection, and
long-term care needs; and

 WHEREAS, While advances in targeted therapies have improved outcomes
for individuals with CLL, disparities in access to innovative
treatments, specialized care, and clinical trials persist, underscoring
the need for continued research and high-quality, accessible care for
all patients; and

 WHEREAS, Blood cancers affect white blood cells and, in some cases,
red blood cells or platelets; and, while no widely recommended screening
tests currently exist, awareness of symptoms and risk factors is
critical to understanding when to seek medical evaluation; and

 WHEREAS, Symptoms of blood cancer include: lymph node swelling,
persistent fatigue, night sweats, fever, difficulty catching breath
and/or unexplained weight loss; and

 WHEREAS, Risk factors for blood cancers include family history,
certain genetic disorders, smoking, exposure to radiation or prior
chemotherapy, immune system dysfunction or immunosuppression (including
in individuals with HIV or those receiving immunosuppressive therapy),
and infection with viruses such as Epstein-Barr; and

 WHEREAS, Significant advances in the treatment of blood
cancers-including leukemia, lymphoma, multiple myeloma, chronic
lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia, and other
hematologic malignancies-have led to innovative therapies such as
cellular immunotherapies (including CAR-T), bispecific antibodies,
antibody-drug conjugates, and targeted precision medicines, resulting in
improved survival rates and quality of life for patients; and

 WHEREAS, All targeted therapies for blood cancers are not
interchangeable, as they differ in mechanism, efficacy, and suitability
for individual patients, and therefore treatment decisions must be
guided by the judgment of physicians to ensure that each patient
receives the therapy best aligned with their specific diagnosis, disease
subtype, overall health, and clinical needs; and

 WHEREAS, There remains a strong and expanding pipeline of potential
therapies for blood cancers, with hundreds of new treatments currently
in development worldwide, reflecting one of the most active areas of
cancer research and offering continued hope for more effective, less
toxic, and potentially curative options in the future; and

 WHEREAS, Although the leukemia survival rate has quadrupled since
1960, in the United States, app